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Purpose of the study
Study 903 is a Phase III trial with a 3-year, double-blind
phase comparing tenofovir DF (TDF) to stavudine in com-
bination with lamivudine (3TC) and efavirenz (EFV). In
the study, TDF was associated with durable efficacy, better
lipid profiles and less lipodystrophy. Study 903E is the
ongoing open-label (OL) extension evaluating up to 10-
year safety and efficacy of a once-daily TDF+3TC+EFV reg-
imen.
Methods
All patients in Argentina, Brazil, and the Dominican
Republic who completed the double-blind (DB) phase
were eligible to roll over to Study 903E and receive a once-
daily regimen of open-label TDF+3TC+EFV.
Summary of results
86 patients (62% male, 70% white, mean age 33 yrs) orig-
inally randomized to TDF continued treatment in the OL
extension. At DB baseline (BL), mean HIV-RNA = 4.9
log10 c/mL and mean CD4 count = 299 cells/mm3. At year
7, 81% (M = F) had HIV-RNA <400 c/mL and 80% (M =
F) had HIV-RNA<50 c/mL; mean CD4 cell increase from
BL = 459 cells/mm3. One patient discontinued study due
to adverse event (elevated amylase/lipase) and four due to
virologic failure. No patient developed K65R mutation.
No patient discontinued due to renal adverse events.
Mean change from BL in glomerular filtration rate (GFR)
by Cockcroft-Gault was +1 mL/min. Decreases in spine
and hip bone mineral density (BMD) by dual energy x-ray
absorptiometry were seen in the first year and remained
stable (mean % change from BL at year 7 in BMD was -
1.5% in spine and -2.6% in hip). No patient sustained
pathologic fractures. Median limb fat was 6.7 kg at year 2
and increased to 8.0 kg at year 7.
Conclusion
Through 7 years of therapy, the once-daily regimen of
TDF+3TC+EFV demonstrated sustained antiretroviral
activity with continued immunologic recovery in antiret-
roviral-naïve patients and was not associated with limb fat
loss or progressive bone loss, nor was it associated with
declines in estimated GFR.
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